The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue

去甲肾上腺素转运蛋白:棕色脂肪组织成像的新靶点

基本信息

  • 批准号:
    8516808
  • 负责人:
  • 金额:
    $ 19.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-01 至 2013-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose tissue Abstract Obesity, and more specifically insulin resistance is characterized by impaired energy expenditure associated adaptive thermogenesis. Adaptive thermogenesis in animals involves activation of brown adipose tissue (BAT), a tissue previously thought to completely regress in adult humans. Biopsy-confirmed BAT in adult humans has revived interest in discovering whether dysfunction in regulation and/or activity of BAT contributes to the pathogenesis of obesity. New methodologies are needed to increase our knowledge of BAT in humans. The purpose of this application is to test a new, mechanistically driven approach using positron emission tomography (PET) imaging of BAT in humans. BAT is strongly innervated and regulated by the sympathetic nervous system. We propose to use a structural feature of the sympathetic nervous system, and image the norepinephrine recycling component, designated the norepinephrine transporter (NET). For this purpose, we will utilize a recently developed, highly selective NET ligand for PET imaging, ((S,S)-[11C]O-methylreboxetine) ([11C]MRB). PET imaging NET has the advantage over [18F]-2-fluoro-deoxy-D-glucose ([18F]FDG) currently in use, because unlike [18F]FDG, it is more specific, and should allow detection of non-stimulated BAT. Our general hypothesis is that the [11C]MRB PET imaging approach will provide a non-stimulated target for BAT that is proportional to BAT mass, but also demonstrates up-regulation with activation of adaptive thermogenesis due to environmental cold exposure. Our aims are divided into both animal, and human experiments. The animal work will directly compare the [11C]MRB and [18F]FDG tracers in awake rats under room temperature and mild cold (40C) conditions for their relationship to interscapular BAT dimensions, mass, and intensity of label. Moreover, we will examine interscapular BAT during in vivo PET imaging after both environmental conditions for [11C]MRB labeling kinetics. Human work will both validate the [11C]MRB PET strategy against the current gold standard of [18F]FDG labeling, using both room temperature and mild cold exposure, as well as provide a preliminary gender comparison of BAT, also using the [11C]MRB PET strategy with room temperature and mild cold exposures. By targeting a primary regulatory system component of BAT, NET, we are establishing a basis for future mechanistic studies of BAT function/dysfunction in obesity and diabetes, as well as for therapeutic approaches for these disorders. PUBLIC HEALTH RELEVANCE: The purpose of this application is to test a new, mechanistically driven approach to image brown adipose tissue (BAT) by targeting its primary regulatory system, the norepinephrine recycling component, designated the norepinephrine transporter (NET). The results from the validation study of NET-PET against FDG-PET will establish a basis for future mechanistic studies of BAT function/dysfunction in obesity and diabetes, as well as for therapeutic approaches for these disorders.
描述(申请人提供):去甲肾上腺素转运蛋白:棕色脂肪组织成像的新靶点摘要肥胖,更具体地说是胰岛素抵抗的特征在于与适应性产热相关的能量消耗受损。动物的适应性产热涉及棕色脂肪组织(BAT)的激活,这种组织以前被认为在成年人中完全退化。成年人中活检证实的BAT重新引起了人们对发现BAT的调节和/或活性功能障碍是否有助于肥胖症发病机制的兴趣。需要新的方法来增加我们对人类BAT的了解。本申请的目的是使用人体BAT的正电子发射断层扫描(PET)成像测试一种新的机械驱动方法。BAT受交感神经系统的强烈支配和调节。我们建议使用交感神经系统的结构特征,并将去甲肾上腺素再循环组件(称为去甲肾上腺素转运蛋白(NET))成像。为此,我们将利用最近开发的用于PET成像的高选择性NET配体((S,S)-[11 C] O-methylreboxylate)([11 C]MRB)。PET成像NET比目前使用的[18 F]-2-氟-脱氧-D-葡萄糖([18 F]FDG)更有优势,因为与[18 F]FDG不同,它更具有特异性,并且应该允许检测非刺激的BAT。我们的一般假设是,[11 C]MRB PET成像方法将为BAT提供与BAT质量成比例的非刺激靶点,但也证明了由于环境冷暴露而激活适应性产热的上调。我们的目标分为动物实验和人体实验。动物研究将直接比较室温和轻度寒冷(40 ℃)条件下清醒大鼠中的[11 C]MRB和[18 F]FDG示踪剂与肩胛间BAT尺寸、质量和标记强度的关系。此外,我们将在体内PET成像过程中检查两种环境条件下[11 C]MRB标记动力学的肩胛间BAT。人类工作将使用室温和轻度冷暴露来验证[11 C]MRB PET策略与[18 F]FDG标记的当前金标准,并提供BAT的初步性别比较,还使用室温和轻度冷暴露的[11 C]MRB PET策略。通过靶向BAT,NET的主要调节系统组件,我们正在为肥胖和糖尿病中BAT功能/功能障碍的未来机制研究以及这些疾病的治疗方法奠定基础。 公共卫生关系:本申请的目的是测试一种新的、机械驱动的方法,通过靶向棕色脂肪组织(BAT)的主要调节系统(去甲肾上腺素再循环组分,称为去甲肾上腺素转运蛋白(NET))来对BAT进行成像。NET-PET对FDG-PET的验证研究结果将为肥胖和糖尿病中BAT功能/功能障碍的未来机制研究以及这些疾病的治疗方法奠定基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YU-SHIN DING其他文献

YU-SHIN DING的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YU-SHIN DING', 18)}}的其他基金

Brain Effects of Lifetime Racial/Ethnic Discrimination on the LC-NE Function and the Risk for Alzheimer's Disease
终生种族/民族歧视对 LC-NE 功能和阿尔茨海默病风险的大脑影响
  • 批准号:
    10214313
  • 财政年份:
    2021
  • 资助金额:
    $ 19.56万
  • 项目类别:
Brain Effects of Lifetime Racial/Ethnic Discrimination on the LC-NE Function and the Risk for Alzheimer's Disease
终生种族/民族歧视对 LC-NE 功能和阿尔茨海默病风险的大脑影响
  • 批准号:
    10667585
  • 财政年份:
    2021
  • 资助金额:
    $ 19.56万
  • 项目类别:
Bispecific Antibody-Based PET Ligands for Imaging Tauopathies
用于 Tau蛋白病成像的双特异性抗体 PET 配体
  • 批准号:
    10086539
  • 财政年份:
    2019
  • 资助金额:
    $ 19.56万
  • 项目类别:
Bispecific Antibody-Based PET Ligands for Imaging Tauopathies
用于 Tau蛋白病成像的双特异性抗体 PET 配体
  • 批准号:
    9809715
  • 财政年份:
    2019
  • 资助金额:
    $ 19.56万
  • 项目类别:
Identifying the mechanisms of action for CBD on chronic arthritis pain
确定 CBD 对慢性关节炎疼痛的作用机制
  • 批准号:
    10018639
  • 财政年份:
    2019
  • 资助金额:
    $ 19.56万
  • 项目类别:
Identifying the mechanisms of action for CBD on chronic arthritis pain
确定 CBD 对慢性关节炎疼痛的作用机制
  • 批准号:
    9895227
  • 财政年份:
    2019
  • 资助金额:
    $ 19.56万
  • 项目类别:
The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue
去甲肾上腺素转运蛋白:棕色脂肪组织成像的新靶点
  • 批准号:
    8189217
  • 财政年份:
    2011
  • 资助金额:
    $ 19.56万
  • 项目类别:
The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue
去甲肾上腺素转运蛋白:棕色脂肪组织成像的新靶点
  • 批准号:
    8325011
  • 财政年份:
    2011
  • 资助金额:
    $ 19.56万
  • 项目类别:
Cocaine, Impulsivity, and PHNO Across Species
可卡因、冲动和跨物种的 PHNO
  • 批准号:
    7797226
  • 财政年份:
    2010
  • 资助金额:
    $ 19.56万
  • 项目类别:
PET IMAGING OF NICOTINIC RECEPTORS
烟碱受体的 PET 成像
  • 批准号:
    7203681
  • 财政年份:
    2004
  • 资助金额:
    $ 19.56万
  • 项目类别:

相似国自然基金

肺炎支原体外排泵ABC Transporter在大环内酯类耐药中的作用机制研究
  • 批准号:
    81672062
  • 批准年份:
    2016
  • 资助金额:
    25.0 万元
  • 项目类别:
    面上项目
一个可能与水稻花粉发育相关的ABC transporter 基因的功能验证与分析
  • 批准号:
    30970274
  • 批准年份:
    2009
  • 资助金额:
    30.0 万元
  • 项目类别:
    面上项目

相似海外基金

Development of novel neuroprotective therapy for ischemic brain injury by controlling fructose transporter
通过控制果糖转运蛋白开发针对缺血性脑损伤的新型神经保护疗法
  • 批准号:
    23K06952
  • 财政年份:
    2023
  • 资助金额:
    $ 19.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Discovery and characterization of a novel acylcarnitine transporter in brown adipocytes
棕色脂肪细胞中新型酰基肉碱转运蛋白的发现和表征
  • 批准号:
    10681400
  • 财政年份:
    2022
  • 资助金额:
    $ 19.56万
  • 项目类别:
Discovery and development of novel glycine transporter-2 inhibitors for the treatment of neuropathic pain
发现和开发用于治疗神经性疼痛的新型甘氨酸转运蛋白 2 抑制剂
  • 批准号:
    10592522
  • 财政年份:
    2022
  • 资助金额:
    $ 19.56万
  • 项目类别:
Understanding epigenetic regulation and modulation of cell stress responses by the cholesterol transporter, scavenger receptor-B1 as a novel target for treating advanced prostate cancer
了解胆固醇转运蛋白、清道夫受体 B1 对细胞应激反应的表观遗传调控和调节作为治疗晚期前列腺癌的新靶点
  • 批准号:
    469855
  • 财政年份:
    2022
  • 资助金额:
    $ 19.56万
  • 项目类别:
    Operating Grants
Structural and functional analysis of novel transporter-type rhodopsin
新型转运蛋白型视紫红质的结构和功能分析
  • 批准号:
    22K19265
  • 财政年份:
    2022
  • 资助金额:
    $ 19.56万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Bioengineering a Novel Therapeutic Transporter that Crosses the Blood Brain Barrier to Treat Brain Disorders
生物工程设计一种新型治疗转运蛋白,可跨越血脑屏障治疗脑部疾病
  • 批准号:
    10324736
  • 财政年份:
    2021
  • 资助金额:
    $ 19.56万
  • 项目类别:
A novel multifunctional role of diverse substrate binding and import by the Haemophilus Sap transporter
嗜血杆菌汁液转运蛋白多种底物结合和输入的新型多功能作用
  • 批准号:
    10582420
  • 财政年份:
    2020
  • 资助金额:
    $ 19.56万
  • 项目类别:
Design, synthesis, and biological assessment of ABC transporter agonists for the development of novel Alzheimer’s disease therapeutics
用于开发新型阿尔茨海默病疗法的 ABC 转运蛋白激动剂的设计、合成和生物学评估
  • 批准号:
    446812474
  • 财政年份:
    2020
  • 资助金额:
    $ 19.56万
  • 项目类别:
    WBP Fellowship
Elucidation of the Function and Physiological Role of a Novel Polyamine Transporter
阐明新型多胺转运蛋白的功能和生理作用
  • 批准号:
    20K07159
  • 财政年份:
    2020
  • 资助金额:
    $ 19.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A novel ECF-type transporter promotes heme acquisition in Staphylococcus lugdunensis to overcome nutritional limitation
一种新型 ECF 型转运蛋白促进路邓葡萄球菌获取血红素以克服营养限制
  • 批准号:
    429484415
  • 财政年份:
    2019
  • 资助金额:
    $ 19.56万
  • 项目类别:
    Research Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了